A Novel Approach to the Management of Obesity, Economically For Multiple Diseases Prevention
Vinod C Tawar*
Family physician and Clinical researcher Clover hill medical clinic, surrey, Canada
Received Date: 28 May, 2019; Accepted Date: 03 June, 2019; Published Date: 12 June, 2019
*Corresponding author: Vinod C Tawar, Family physician and Clinical researcher Clover hill medical clinic, surrey, b.c. Canada. Email: tawar.vinod@yahoo.com
Citation: Tawar VC (2019) Peripheral Vascular Disease Treatment via an Innovative Topical Formulation “Perivasc”. Adv Endo and Dia. AEAD- 106.
Abstract
There is a well-recognized fact that obesity is a causative factor to many life-threatening diseases. In general, lifestyle, family history, inactivity, medications etc. Are known contributors however, irrespective of contributors losing weight has been a challenging issue i.e. cost, motivation, compliance effectiveness has been impractical for many suffering from obesity leads to diabetes, ischemic heart disease, de-ression, arthritis , all-cause mortality, hypertension, hyperlipidemia, stroke, gallbladder disease, obstructive sleep apnea, asthma, pancreatic and reproductive organs related cancers.
Our current research was conducted over 12-16 weeks and included 38 patients. A review of their medical history revealed poor heating habits, depression, diabetes, hypertension and inactivity to least a few. The method consisted of training patients to self-inject subcutaneously over abdominal surface on lateral flanks alternatively every 3 days, under supervision until they were effectively injecting vitamin b12 o.5cc and pyridoxine hydrochloride each and on subsequent visit they would to other flank on a similar area. Once trained the patients were seen on a weekly basis. A pre-treatment lab assessment was done and at the conclusion of treatment, however they were weighed at each visit. Additional measures included calorie-wise diet and light aerobic exercises 20-30 minutes 3 times per week.
Past Investigations
Govt. of Canada in 1994 had published an article about the obesity and its impact on economy and health [1]. Subsequently in 2007, an algorithm of the management of obesity was outlined [2]. Next Hainer, et al. In 2008, discussed the role of obesity in diabetes care supplement [3] in 2010 , cdc guidelines emphasized the significance of dietary control in preventing obesity [4] next , executive summary of guidelines included management of overweight and obesity in adults in 2013 [5]. Subsequently in 2013, a publication highlighted on the issue of health consequences of being overweight in 2013 [6]. On a following publication in 2014, guidelines for the management of overweight and obesity in adults were stated [7]. European guidelines in 2015 included for obesity management in adults [8] Austric, et al. in 2018 highlighted on changes in food rewards considerations during weight management aspect [9]. Next, Drummen M, et al. Studied dietary protein and energy balance in relation to obesity and co-morbidity [10] finally in 2o18, o’neil p.m. et al. did a comparative study of semaglutide and liraglutide 7 placebo in terms of efficacy and safety. The end results showed semaglutide in combination with physical activity, dietary and activity counselling showed more effectiveness and better tolerance [11].
Method
Patients Selection
A common issue in majority of the patients was having diabetes and of Indiaorigin, attributed to surrounding population. The distribution of male to female ratio was approximately 1:5, in the age category of 30 to 72 in males and females from 22 to 58. Their past treatments contributing or absence of included hypothyroidism in activity, oa , dmm , depression,, chronic pain , gad , fatigue , , obesity for unidentified factors, , ischemic heart disease, soft tissue injuries, etc.. Other factors contributing to obesity were life styles, family history, eating disorders and drugs (glyburide, phenothiazines, gliclazide and insulin).
Results Enclosed in Tables Number of Patients: 26
No.
INIT
AGE
DUR. DM
TX PERIOD
1
SM
55
2 YEARS
7 DAYS
2
INM
85
10 DAYS
10 DAYS
3
J. K
62
5 MONTHS
3 DAYS
4
SK
35
3 YEARS
7 DAYS
5
H. V
76
2 YEARS
2 MONTHS
6
LY
57
PVD 7 YEARS
2 MONTHS
7
CC
59
4 YEARS
2 MONTHS
8
SC
54
2 YEARS
1 MONTH
9
EH
52
2 YEARS
1 MONTH
10
JL
76
10 YEARS
3 MONTHS
11
NN
65
8 YEARS
1 MONTH
12
JN
60
3 YEARS
2 WEEKS
13
DG
76
10 YEARS
2 MONTHS
14
YH
62
3 YEARS
2 MONTHS
15
FH
57
8 YEARS
3 MONTHS
16
WS
89
15 YEARS
2 MONTHS
17
AR
52
10 YEARS
4 MONTHS
18
AM
57
12 YEARS
6 MONTHS
19
VT
75
20 YEARS
4 MONTHS
20
PT
69
4 YEARS
1 MONTH
21
KL
45
6 YEARS
1 MONTH
22
SS
62
7 YEARS
3 MONTHS
23
LK
59
10 YEARS
2 MONTHS
24
GP
52
4 YEARS
1 MONTH
25
KS
57
20 YEARS
3 MONTHS
26
HA
62
5 YEARS
4 MONTHS
Notes:
Most- Diabetic Patients
A few- Smokers
One- Accidental Freezing
Age 35-89 Years
Duration DM 2- 20
Duration TX 3D – 3MOS
Relapse
No.
INIT
AGE
SEX
Pre WT
Past HX
Post WT
DUR.TX
Changes BMI
Outcome
1
JL
32
F
178
HYPOTHY
161
16
4
FERTILITY
2
KL
37
M
210
DM
200
12
1
DEPC.AIC
3
ST
52
F
162
A
148
16
3
A
4
EH
49
F
172
OA
165
14
3
DEC.PAIN
5
SD
58
F
180
CP
126
16
4
DEC.PAIN
6
DA
72
M
190
DM
180
12
3
DEC.AIC
7
AC
54
F
172
DEP.
168
12
2
MOT.
8
SC
58
F
155
CP
142
12
2
DEC.PAIN
9
SS
88
F
170
OA
151
16
3
DEC.PAIN
10
AG
30
M
180
GAD
163
16
4
MOT.
11
BP
32
F
172
FAT
160
12
1
MOT.
12
RC
22
F
164
FAT
141
12
3
MOT.
13
VV
30
F
182
OBE
162
16
4
MOT.
14
CS
54
F
189
IHD
175
12
3
A
15
BA
42
M
170
DM
159
16
2
DEC.AIC
16
VK
44
F
168
STIGAD
155
12
3
A, DEC.PAIN
17
VJ
24
F
150
DM
135
12
3
DEC.PAIN
18
SR
49
F
155
DM
145
12
1
DEC.PAIN
19
BD
62
F
200
DM
190
12
1
DEC.PAIN
20
JS
49
F
201
DM
185
12
3
DEC.PAIN
21
SU
60
F
210
DM
190
10
3
MOT.
22
GL
39
F
176
OBE
175
12
3
DEC.AIC MOT
23
PC
41
M
195
DM
172
12
3
DEC.AIC MOT
24
PS
26
M
200
FAT
188
10
4
MOT.
25
SM
47
F
182
ETH
176
08
1
ETH,GAD
26
JU
49
F
162
FAT
150
12
2
MOT.
27
TI
55
F
170
OA
148
16
3
DEC.PAIN
28
MR
58
F
172
FAT
149
16
2
MOT.
29
KN
31
F
165
DED.
151
12
2
DEC.PAIN
30
AR
52
F
186
DM
172
12
2
DEC.AIC
31
GG
31
F
172
FAT
164
12
2
MOT.
32
SA
52
F
172
DM
158
16
2
DEC.AIC
33
AH
49
F
176
DM
152
14
2
DEC.PAIN
34
SD
36
F
168
DM
158
10
2
MOT.
35
KS
40
F
165
DM
143
10
3
DEC.AIC
36
SD
52
F
168
FAT
156
08
2
MOT.
Abbreviations:
MOT: Motivation
PREG: Pregnancy
A: Increased/Active
FAT: Fatigue
Results at the conclusion of study indicated highest compliance, motivation, and a consistent weight loss of 8-10 pounds / month. The lost weight mostly remained sustained. Most importantly, the approach remained most economical (30-40 dollars) for a 12-14 week period. Prior to participation in the study some patients had spent thousands of dollars at commercial facilities with rigid controls and had regained the weight drastically at the rate it was lost. This was a main reason of designing the study. A 56 year female patient had lost 35 pounds resulting in a BMI of normal value. Her visit after 3 years showed a sustained weight loss. The parameters considered in the documentation of results are age, sex, pre tx wt. past hx, post tx weight, duration of tx, changes in bmi, and outcome of the research. The participants did not experience any adverse reactions from vitamin injections.
Factors Affecting Weight Loss
- Compliance, motivation
- Diet- calories control.
- Pre-morbid illnesses
Discussion
The duration of study was 16 weeks. The study included 36 participants. A majority of participants were from India with history of having diabetes, in age group 24to 88. Illnesses other than diabetes were hypothyroidism, chronic pain, osteo-arthritis, fatigue, obesity, fatigue, generalized anxiety disorder and ischemic heart disease. The duration of participation included 8 to 16 weeks. The resulting decrease in bmi included 1 to 4 improving fertility, decreasing severity of pain, increasing motivation towards fitness and decreasing severity of diabetes.
In summary, the weight loss approach being an economical option with pro-active patient’s involvement appears to be a valuable, feasible process of multiple diseases prevention in Canada overall cost of medications was approx. 40 dollars/ 3 months.
References
- Canada publ. “ obesity in Canada- health and economic implications impact “ 1994
- “ALGORITHM OF THE MGT. OF OBESITY” in cmajapril 2007
- “Diabetic Care Suppl,” 2:5269-77:31, 2008.
- “cdc guidelines in http // , www.healthgov. /dietary guidelines. 2010.
- American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel (2014) Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 2: S5-39.
- “Health Consequences of Being Overweight” march 2012, who publ.
- “Michael Jensen in “exec. Summary: guidelines for the management of overweight and obesity in adults in adults in obesity” a research journal. july 2014.
- Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, et al. (2015) European Guidelines for Obesity Management in Adults. Obes Facts 6: 402-424.
- Oustric P, Gibbons C, Beaulieu K, Blundell J, Finlayson G. Changes in food reward during weight management interventions - a systematic review. Obes Rev 12: 1642-1658.
- Drummen M, Tischmann L, Gatta-Cherifi B, Adam T, Westerterp-Plantenga M (2018) Dietary Protein and Energy Balance in Relation to Obesity and Co-morbidities. Front Endocrinol (Lausanne) 6: 9:443
- O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, et al. (2018) fficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392: 637-649.